Pulmonary Arterial Hypertension (PAH) Therapeutics: A Global Strategic Business Report
San Jose, California (PRWEB) July 09, 2012
Follow us on LinkedIn – Although a disease of rare occurrence, the complexities associated with pulmonary arterial hypertension (PAH) makes it a life-threatening disorder. Despite the availability of effective treatment options at present, no medication proves to be full proof panacea for PAH. Room for improvement exists and this lends considerable scope to the ever expanding PAH therapeutics market. With the treatment options for PAH patients getting wider by the day, increasing number of PAH patients are now able to manage without the need of being hospitalized. Innovations in PAH related clinical trials over the years have resulted in the availability of a wide range of effective medication options, whereby patients have access to the timely and speedier treatment options. As per statistics, medical advancements in the field of PAH have reduced the mortality rate by more than 40%, and also the hospitalization rates, with the admission rates in hospitals shrinking by about 57%. The market at present is primarily driven by high unmet needs in terms of safety and efficacy profiles of the available therapies. Need for improvement in present treatment procedures lends a huge potential for expansion in the coming years.
As of now, the PAH drugs market is primarily characterized by the widespread use of ERAs (Endothelin Receptor Antagonist). Tracleer represents the leading drug in the ERA category, followed by Letairis from Gilead. Being the first of its kind to enter the PAH market, FDA approved Tracleer from Actelion Ltd., witnessed a steep rise in sales, undisputedly dominating the market ever since its approval in 2001. This was followed by the entry of other FDA approved drugs such as Remodulin in 2002 and 2004, Ventavis in 2004, Revatio in 2005 and Letairis in 2007.
Tracleer forms the largest selling drug, accounting for a major chunk of the US PAH therapeutics market. Other significant market contenders include Pfizer’s Revatio with a market share of 14%, followed by Remodulin accounting for about 13% share in 2011. However, with the increasing number of clinical trials in the PAH field, the market is increasingly becoming fragmented. Riociguat from Bayer is one such upcoming drug that is anticipated to pose serious threat to Tracleer’s protracted reign. Currently under Phase III trials, Riociguat would be the first drug belonging to the sGC (soluble guanylate cyclase) class in the market.
In the near term, various factors are expected to aid in the growth of the PAH market, which include launch of the pipeline drugs, development of innovative safer and efficient new drugs, and increased competition amongst existing players resulting in further research and development activities. In addition, combination drugs such as epoprostenol and sildenafil, plus epoprostenol and bosentan, are also expected to propel market growth. However, growth of the market is expected to be hampered by the patent expiry of Tracleer in 2015, resulting in the slowdown in the market growth post 2015.
Region-wise, the US constitutes the largest regional market, as stated by a new research report on Pulmonary Arterial Hypertension Therapeutics. PAH patient population in the US predominantly comprises Class II and Class III patient type. Although the patient population is not substantial in the US, the amount of expenses incurred on the treatment by the affected population renders it a promising market. Also, in many instances PAH has been reported to be under-diagnosed – a fact indicating further growth prospects for the PAH market. Emerging markets in the regions such as Asia-Pacific and Latin America are among the fastest growing regional markets for PAH. With PAH being a rapidly progressive disease, with a high mortality rates and less survival period of around 4 years following diagnosis, efficacy, dosing convenience, and side effects profile has emerged as key competitive factors for most of the leading players.
Key players profiled in the report include Actelion Pharmaceuticals Ltd., Bayer Healthcare Pharmaceuticals, Eli Lilly and Company, Nippon Shinyaku Co., Ltd., United Therapeutics Corp., Arena Pharmaceuticals Inc., Pfizer Inc., among others.
The research report titled “Pulmonary Arterial Hypertension (PAH) Therapeutics: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive market overview, current market trends, growth drivers, currently marketed products, pipeline analysis, strategic corporate developments, FDA approvals, recent launches, and profiles of major/niche global and regional market participants. The report provides annual sales estimates/projections for the years 2010 through 2018 in US$ million for geographic markets – US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World markets. The report also provides market size estimates and projections for individual drugs, including Endothelin Receptor Antagonist (ERA) (Letairis/Volibris, Macitentan, Thelin (Sitaxentan), Tracleer) Prostacyclin (Epoprostenol/Veletri, Flolan, Remodulin, Selexipag, Tyvaso, Ventavis) PDE-5 Inhibitors (Cialis/Adcirca, Revatio (Sildenafil)), Soluble Guanylate Cyclase (sGC) Stimulators (Riociguat). The study also provides historic data for an insight into the evolution of the PAH therapeutics market over the period 2004 through 2009.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/